Effect of simvastatin on cardiac fibrosis in patients with essential hypertension.
- Author:
Guo-Gang ZHANG
1
;
Sai-Dan ZHANG
Author Information
1. Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China. xyzzgg@sina.com
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Angiotensin-Converting Enzyme Inhibitors;
therapeutic use;
Antihypertensive Agents;
therapeutic use;
Benzazepines;
therapeutic use;
Drug Therapy, Combination;
Female;
Fibrosis;
etiology;
prevention & control;
Humans;
Hypertension;
complications;
drug therapy;
Male;
Middle Aged;
Myocardium;
pathology;
Simvastatin;
therapeutic use
- From:
Journal of Central South University(Medical Sciences)
2005;30(3):280-282
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the effect of simvastatin on myocardiac fibrosis in patients with essential hypertension (EH).
METHODS:Sixty EH patients were randomly assigned into 2 groups: Benazepril (10 mg/d) group (n = 28) and simvastatin (20 mg/d) + benazepril (10 mg/d) group. Procollagen type III aminoterminal peptide (PIIIP), and procollagen type IV aminoterminal peptide (PIVP) levels in serum as well as transforming growth factor beta 1 (TGFbeta1) level in plasma were measured by radioimmunoassay (RIA) before and 6 months after the treatment. Doppler ultrasound recordings were obtained from all patients before and 6 months after the treatment to determine several parameters related to the left ventricular anatomy and function.
RESULTS:After 6 month of treatment, the mean blood pressure (MBP), PIIIP, PIVP, TGFbeta1, left ventricular mass index (LVMI), interventricular spectum dimension (IVSD), and left ventricular posterio wall dimension (LPWD) in the 2 groups were significantly lower than those before the treatment. TGFbeta1 decreased in the simvastatin and benazepril group compared with the benazepril group (P < 0.01). The ratio of early diastolic blood flow velocity of mitral valve (VE) and blood flow velocity of atrium systolic period (VA) in the 2 groups significantly increased after 6 months of treatment, and the ratio in the simvastatin and benazepril group was significantly higher than that in the enazepril group (P < 0.05).
CONCLUSION:Angiotension converting enzyme inhibitor combined with simvastatin is helpful to reduce the myocardial fibrosis and to improve the left ventricular hypertrophy and diastolic function in EH patients.
